The Conference Floor and the Capital Data Are Saying the Same Thing.
Before SAWC, I wrote this:
"2025 was a positioning year. 2026 is when the deals get made."
I spent last week in Charlotte finding out if that was true.
It was.
SAWC Spring 2026 was the first major industry gathering since the CMS reimbursement restructuring fully activated, and the floor told a story that the capital data had already been signaling for months. The companies that built around clinical evidence, reimbursement credibility, and diversified channels were having fundamentally different conversations than the ones that didn't. The divergence wasn't subtle.
What struck me coming out of Charlotte is how cleanly the conference signal and the capital data align. That doesn't always happen. Conference energy is often disconnected from where money actually flows — a function of marketing budgets, booth presence, and the well-documented gap between clinical enthusiasm and commercial reality.
This week, they converged. Here's how to read them together.
What SAWC showed: Debridement is the category in motion.
The conference added a featured plenary on debridement in direct response to attendee demand — the first time in recent years the topic has anchored a general session rather than a subspecialty track. MediWound presented data supporting EscharEx as a biologically active first-line intervention, backed by a newly published U.S. expert consensus in WOUNDS. Kane Biotech presented revyve pH-normalization data showing meaningful wound size reductions tied to a mechanism the market has largely undervalued. The SANTYL-or-sharp-debridement default is being questioned at a clinical level with more intensity than at any prior SAWC in memory.
What the Capital Signal confirmed: Early-stage capital is concentrating in differentiated platforms.
Series A and B funding activity ran 2.3x higher than late-stage in Q1. The categories drawing that early capital are precisely the ones generating clinical momentum on the conference floor — enzymatic debridement, AI-assisted diagnostics, wound bed preparation technologies. Investors are not funding incremental improvements on existing platforms. They are funding differentiated mechanisms with a credible path through the post-CMS reimbursement environment.
What SAWC showed: AI diagnostics is transitioning from concept to clinical infrastructure.
Spectral AI's +18.49% single-week move coincided with a CFO hire that signals commercial readiness, not further development. Swift Medical's booth presence was less about showcasing technology and more about fielding integration conversations — health systems, payors, and enterprise wound care programs asking how to operationalize what they've already seen work in pilots. The conversation has shifted from "does this work" to "how do we scale this."
What the Capital Signal confirmed: Strategic buyers are acquiring infrastructure, not products.
The M&A activity tracked in Q1 reflects the same logic. Acquirers are not buying innovation — they are buying proven clinical infrastructure, channel access, and reimbursement-credentialed platforms at a moment when the CMS filter is sorting the market in real time. Every verified exit in the BTK dataset with an Innovation Score ≥7.0 that reached commercial scale was acquired within 18–36 months of its last venture round. The average Innovation Score across those exits: 8.11. That pattern is not slowing down. It is accelerating.
What SAWC showed: The reimbursement story has a second chapter.
The CAMP restructuring conversation at SAWC was not about whether it happened. It was about who adapted. The companies with documentation infrastructure, diversified channel strategies, and a clinical evidence base were talking about Q1 volume. The ones that didn't build those things were not at the conference in the same way — smaller booths, fewer staff, different energy. The floor is already pricing in who survived the restructuring.
What the Capital Signal confirmed: The sorting is reflected in the funding data.
Late-stage capital is flowing toward companies with demonstrated reimbursement navigation. The profile of Q1 deals — size, structure, investor composition — skews toward platforms that have already proven they can operate in the post-December 2024 environment. Early-stage capital is going toward differentiated mechanisms. The middle — undifferentiated products with legacy reimbursement dependence — is where the stress is concentrated.
The BTK read:
When conference floor signal and capital allocation data converge on the same thesis, it's worth paying attention. The BTK market is not in a period of general growth. It's in a period of sorting — and the companies emerging on the right side of that sort share a common profile: clinical evidence, reimbursement credibility, and commercial infrastructure capable of operating in the post-December 2024 environment.
This week, BTK launches the Q1 Capital Signal — a new free quarterly report tracking where money is actually moving across wound care, limb salvage, vascular intervention, and foot and ankle. It's live now at https://www.belowtheknee.co/capital-signal.
The Q1 Capital Signal is the first edition of a free quarterly BTK resource designed to track this in real time — deal activity, funding flows, talent signals, and international expansion trends across wound care, limb salvage, vascular intervention, and foot and ankle.
The conference told you where the market is going. The data confirms it.
— Scott | Below The Knee
Found this useful? Forward it to a colleague in BD, strategy, or investment who covers this space.
Not a subscriber yet? → click here
See you Friday. — Scott.